Association of Apolipoprotein C3 Levels and Hepatic Steatosis: A Follow-Up Study
暂无分享,去创建一个
[1] M. Kostapanos,et al. Recent developments in pharmacotherapy for hypertriglyceridemia: what’s the current state of the art? , 2019, Expert opinion on pharmacotherapy.
[2] R. Fan,et al. Association between body mass index and fatty liver risk: A dose-response analysis , 2018, Scientific Reports.
[3] H. Burdett. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia , 2016, Annals of clinical biochemistry.
[4] D. Gaudet,et al. Targeting APOC3 in the familial chylomicronemia syndrome. , 2014, The New England journal of medicine.
[5] A. Munshi,et al. Apolipoprotein C3 gene polymorphisms in Southern Indian patients with nonalcoholic fatty liver disease , 2014, Indian Journal of Gastroenterology.
[6] Minrui Li,et al. Apolipoprotein C3 (-455T>C) polymorphism confers susceptibility to nonalcoholic fatty liver disease in the Southern Han Chinese population. , 2014, World journal of gastroenterology.
[7] K. R. Rao,et al. Pooled genetic analysis in ultrasound measured non-alcoholic fatty liver disease in Indian subjects: A pilot study. , 2014, World journal of hepatology.
[8] Y. Xin,et al. Lack of association between apolipoprotein C3 gene polymorphisms and risk of nonalcoholic fatty liver disease in a Chinese Han population. , 2014, World journal of gastroenterology.
[9] D. Gaudet,et al. AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III SIGNIFICANTLY DECREASES APOLIPOPROTEIN C-III, TRIGLYCERIDES, VERY-LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER, AND INCREASES HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND PARTICLE NUMBER IN HYPERTRIGLYCERIDEMIC PATIENTS ON A FIBRATE , 2014 .
[10] M. Taskinen,et al. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population , 2013, Obesity.
[11] H. Makhlouf,et al. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.
[12] Richard G. Lee,et al. Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.
[13] Anoop Misra,et al. Non-Alcoholic Fatty Liver Disease Is Closely Associated with Sub-Clinical Inflammation: A Case-Control Study on Asian Indians in North India , 2013, PloS one.
[14] A. Hofman,et al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. , 2012, Journal of hepatology.
[15] R. Hegele,et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia , 2012, Journal of internal medicine.
[16] N. Lundbom,et al. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease , 2012, Journal of gastroenterology and hepatology.
[17] R. Aggarwal,et al. APOC3 and PNPLA3 in non‐alcoholic fatty liver disease: Need to clear the air , 2012, Journal of gastroenterology and hepatology.
[18] M. Zappa,et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. , 2011, Journal of hepatology.
[19] F. Leonetti,et al. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans , 2011, Lipids in Health and Disease.
[20] Jonathan C. Cohen,et al. Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance , 2011, Hepatology.
[21] G. Pera,et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain , 2010, European journal of gastroenterology & hepatology.
[22] Benjamin M Yeh,et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? , 2009, Clinical imaging.
[23] J. O’Connell,et al. A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.
[24] R. Rector,et al. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. , 2008, World journal of gastroenterology.
[25] Y. Nie,et al. Prevalence of fatty liver disease and its risk factors in the population of South China. , 2007, World journal of gastroenterology.
[26] Yuichi Harano,et al. The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reflects the Metabolic Syndrome and Visceral Fat Accumulation , 2007, The American Journal of Gastroenterology.
[27] G. Bedogni,et al. Incidence and natural course of fatty liver in the general population: The Dionysos study , 2007, Hepatology.
[28] H. Nagahara,et al. Clinical significance of fatty liver associated with metabolic syndrome , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[29] P. Libby. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. , 2007, Circulation research.
[30] K. Lindor,et al. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. , 2007, Clinics in liver disease.
[31] P. Portincasa,et al. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. , 2006, The Journal of nutrition.
[32] W. Koenig,et al. Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults , 2006, BMC public health.
[33] Zamir Halpern,et al. Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures , 2006, Liver international : official journal of the International Association for the Study of the Liver.
[34] P. Libby,et al. Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells , 2006, Circulation.
[35] G. Bedogni,et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.
[36] A. Jenkins,et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. , 2005, Diabetes care.
[37] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[38] G. Bedogni,et al. The epidemiology of fatty liver , 2004, European journal of gastroenterology & hepatology.
[39] Nancy Dekki,et al. Apolipoprotein CIII promotes Ca2+-dependent β cell death in type 1 diabetes , 2004 .
[40] H. Kim,et al. Insulin resistance and C‐reactive protein as independent risk factors for non‐alcoholic fatty liver disease in non‐obese Asian men , 2004, Journal of gastroenterology and hepatology.
[41] J. Levy,et al. Use and abuse of HOMA modeling. , 2004, Diabetes care.
[42] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.
[43] G. Assmann,et al. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. , 2003, Atherosclerosis.
[44] N. Wareham,et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids in middle-aged men. , 2003, Biochimica et biophysica acta.
[45] G. Marchesini,et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.
[46] M. Pfeffer,et al. VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial , 2000, Circulation.
[47] M. Bellini,et al. The bright liver syndrome. Prevalence and determinants of a "bright" liver echopattern. , 1997, Italian journal of gastroenterology and hepatology.
[48] A. R. Frisancho. Physical Status: The Use and Interpretation of Anthropometry , 1996, The American Journal of Clinical Nutrition.
[49] T. Goto,et al. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.
[50] C. Tiribelli,et al. Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study , 1994, Hepatology.
[51] A. Pavie,et al. Doppler echocardiography for the diagnosis of acute cardiac allograft rejection. , 1988, Journal of the American College of Cardiology.
[52] J. Maxwell,et al. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. , 1986, British medical journal.
[53] J. Seilhamer,et al. Isolation and sequence analysis of the human apolipoprotein CIII gene and the intergenic region between the apo AI and apo CIII genes. , 1984, DNA.
[54] P. Demacker,et al. Apolipoprotein C in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia , 1982, Diabetologia.
[55] W. Brown,et al. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. , 1972, Biochemical and biophysical research communications.
[56] J. Larosa,et al. A specific apoprotein activator for lipoprotein lipase. , 1970, Biochemical and biophysical research communications.
[57] L. N. Valenti,et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.
[58] C. Konda,et al. Chylomicronemia syndrome. , 2009, Indian journal of dermatology, venereology and leprology.
[59] Tetsuji Sato,et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. , 2006, Annals of internal medicine.
[60] H. Jörnvall,et al. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[61] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.
[62] J. McGarry,et al. Fatty acids, lipotoxicity and insulin secretion , 1999, Diabetologia.
[63] P. B. Eveleth,et al. Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee , 1996 .
[64] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.
[65] P. Nestel,et al. Apoprotein C metabolism in man. , 1982, Advances in lipid research.